Skip to main content
Premium Trial:

Request an Annual Quote

JW Therapeutics Launches Phase I T-Cell Immunotherapy Trial in Certain Liver Cancer Patients

NEW YORK – JW Therapeutics on Tuesday said it is starting a Phase I trial of its autologous T-cell immunotherapy candidate JWATM214 in patients with GPC-3-expressing advanced hepatocellular carcinoma.

JWATM214 is a GPC-3-targeted cell therapy developed using the Artemis platform from Eureka and incorporates T-cell anti-exhausting technology from Lyell. Shanghai-based JW licensed rights to those technologies in 2020 and has been using them to develop, manufacture, and commercialize products in China.

In the recently launched Phase I trial, JW Therapeutics will assess the safety and tolerability of JWATM214 and determine a recommended Phase II dose in patients with GPC-3-expressing advanced hepatocellular cancer. Researchers will also gather information on the treatment's pharmacokinetics and preliminary efficacy in this subset of patients.

GPC-3 (glypican-3) is overexpressed in hepatocellular cancer, which accounts for 85 percent to 90 percent of primary liver cancer. China has 466,000 newly diagnosed patients and 422,000 deaths per year — the highest rate in the world. Median progression-free survival among patients after first- and second-line standard therapy is about six months.